32 results about "Abzyme" patented technology

The present application relates to the technical field of biotechnology, and particularly relates to a D-dimer chemiluminescence assay kit. The present application provides a D-dimer chemiluminescence assay kit, which comprises a magnetic particle suspension (immunomagnetic beads) coated with D-dimer antibody 1, alkaline phosphatase-labeled D-dimer antibody 2 (enzyme-labeled antibody) and a calibrant. The immunomagnetic beads and the enzyme-labeled antibody are prepared by chemical coupling and stored in a buffer containing a soluble high molecular material, which can effectively improve the detection sensitivity and repeatability. The kit can be used in combination with a substrate solution containing a chromogenic substrate such as adamantane and its derivative AMPPD or APS-5 for a full-automatic immune test system, and the content of D-dimer in plasma or whole blood can be determined by a chemiluminescence instrument. The kit has high detection sensitivity and good repeatability.

A method for producing an antibody κ-type light chain having enzyme activity or improved enzyme activity includes: a modification step for modifying a polynucleotide encoding an antibody κ-type light chain in which the variable region is a polypeptide comprising an amino acid sequence in which the 95th amino acid residue from the N-terminal of the variable region by the Kabat classification is a proline residue so that the proline residue is deleted or substituted to obtain a polynucleotide encoding an antibody κ-type light chain in which the variable region is a polypeptide comprising an amino acid sequence in which the 95th amino acid residue from the N-terminal of the variable region by the Kabat classification is deleted or an amino acid residue other than a proline residue; and an expression step for expressing the antibody κ-type light chain having enzyme activity by an intracellular or extracellular expression system using an expression vector including the polynucleotide encoding an antibody κ-type light chain from after the modification step.

The invention discloses a bridging antibody, an enzyme-labeled polymer as well as a preparation method and application of the bridging antibody. The bridging antibody is prepared by the following steps: performing enzyme digestion, purification, reduction, sulfydryl protection and coupling on a polyclonal antibody and an anti-DMT-biotin monoclonal antibody through pepsin, and then purifying to obtain a heterodimer product polyclonal antibody-Fab '-Linker-Fab'-anti-DMT-biotin; hRP is subjected to maleimide and then coupled with a sulfhydrylated polymer to obtain a polymer enzyme, and then the polymer enzyme is coupled with a small molecule DMT-biotin to obtain the enzyme-labeled polymer which is specifically combined with the bridging secondary antibody. The obtained bridging antibody and enzyme-labeled polymer are used for preparing a kit for three-stage amplification of immunohistochemical signals, through cooperation of all the components, low-abundance antigens in tissues can be better detected, and the false positive rate is greatly reduced.

The invention provides an anti-neocrown N protein human monoclonal antibody, an enzyme-linked immunosorbent assay kit and application of the anti-neocrown N protein human monoclonal antibody and the enzyme-linked immunosorbent assay kit. The anti-neocoronal N protein human monoclonal antibody is obtained from N protein of human immune neocoronal virus, a heavy chain and a light chain of the anti-neocoronal N protein human monoclonal antibody have variable regions and complementary determining regions, and the anti-neocoronal N protein human monoclonal antibody is specifically combined with neocoronal N protein; and through paired use of the antibodies, the kit has strong anti-interference capability, good specificity and high sensitivity on clinical new crown detection.

The invention discloses an electrochemiluminescence detection method of PARP enzyme, a kit and application thereof. The electrochemical luminescence detection method for detecting PARP enzyme comprises the following steps: (1) mixing human whole blood, a PARP inhibitor and a PARG inhibitor, incubating, and centrifuging to obtain human peripheral blood mononuclear cells; (2) collecting a human peripheral blood mononuclear cell precipitate for cracking, detecting the total protein concentration, adding a sample, adding a cell lysis solution into an electrochemical luminescent plate for incubation, and adding a PARP enzyme detection antibody for re-incubation; and (3) adding a detection secondary antibody for incubation to form a capture antibody-PARP enzyme-detection antibody-secondary antibody complex, and adding plate reading liquid for plate reading. The electrochemical luminescence detection method and the kit have the characteristics of high sensitivity, high specificity, high accuracy, high precision and simple operation method, and can quantitatively detect the content of PARP enzyme.

This invention discloses an enzyme-linked immunosorbent assay (ELISA) kit for detecting benzo[a]pyrene in edible oil, kitchen fumes, and vehicle exhaust. The kit includes: a sample reconstitution solution, an enzyme conjugate / antibody diluent, a standard / sample diluent, a benzo[a]pyrene standard, a benzo[a]pyrene-specific mouse monoclonal antibody, an enzyme conjugate, an ELISA plate coated with benzo[a]pyrene antigen, a chromogenic solution, a stop solution, and a washing solution. This invention also discloses a method for detecting benzo[a]pyrene in edible oil, kitchen fumes, and vehicle exhaust using the kit, including sample pretreatment, ELISA detection, and result processing and analysis. The sample reconstitution solution, enzyme conjugate / antibody diluent, and standard / sample diluent provided by this invention overcome the solubility problem of benzo[a]pyrene in edible oil, kitchen fumes, and vehicle exhaust while maintaining antibody sensitivity, and can also significantly improve antibody titer, thus possessing significant value for widespread application.

The application provides a flumetover half antigen, artificial antigen and antibody and a preparation method of the flumetover half antigen, artificial antigen and antibody, and application of the flumetover half antigen, artificial antigen and antibody to an enzyme-linked immunoassay kit, the kit comprising: an enzyme-labeled plate coated with a coating agent, a flumetover standard solution, a flumetover antibody, an enzyme conjugate concentrate, an enzyme conjugate diluent, a substrate developing solution, a termination solution and a washing solution, wherein the coating agent is a flumetover conjugate antigen, the enzyme conjugate is an enzyme-labeled flumetover antibody, and the flumetover antibody is obtained by immunizing animals with an immunogen. The application further discloses a method for detecting flumetover by using the enzyme-linked immunoassay kit, which comprises the following steps: firstly, sample pretreatment, then, detection by using the kit, and finally, analysis of the detection result. The enzyme-linked immunoassay kit provided by the application can be used for detecting the content of flumetover in vegetable and fruit samples, and has the advantages of simple operation, low cost, high sensitivity, on-site monitoring and suitability for screening of a large number of samples.

The invention relates to a method for determining kininogenase and a used kit. On one hand, the invention relates to a kit for determining the content of kininogenase in human plasma, the kit comprises a test solution for testing, an antigen standard substance, a capture antibody, an enzyme-labeled antibody and a test method description file which are separately packaged by containers, and the test solution comprises PBS, PBST, a washing solution, a confining solution, a sample diluent, a stop solution, a coating buffer solution, a color developing solution A and a color developing solution B. The invention also relates to a method for determining the content of kininogenase in human plasma by using the kit. According to the kit and the method provided by the invention, the amount of endogenous kininogenase or exogenous kininogenase in a human body can be accurately and effectively measured, and a beneficial tool is provided for diagnosis and treatment of clinical diseases.

Methods for target, biomarker, and patient selection discovery in central nervous system disorders utilizing patient-derived cellular models, spatial proteomics, and machine learning. The method generates neural cells from forebrain regions from induced pluripotent stem cells, performs cell-type specific proteome profiling using antibody-enzyme conjugates and spatial proteome profiling, and applies statistical data augmentation to sparse biological datasets. Machine learning classifiers with SHAP-based feature importance identify ranked biomarkers from mass spectrometry data. The platform enables patient stratification by linking molecular signatures to symptom severity, drug screening through biomarker modulation, and diagnostic applications. Kits comprising antibodies for biomarkers including antibodies for biomarkers identified by the method facilitate implementation. Applications include autism spectrum disorder, rare neurodevelopmental disorders, schizophrenia, epilepsy, Alzheimer's disease, and Parkinson's disease.

A compound having the structure (I) is provided. The compound is useful as a therapeutic agent in the form of a lipoplex, or in a form of a polyplex, in a form of a lipid nanoparticle, or in a form of a liposome, or in a form of a micelle, or in a form of an emulsion including a drug, vaccine, oligonucleotide, antibody, enzyme, protein, small molecule, or nucleotide.

The invention discloses a monoclonal antibody combination for Brucella detection and application thereof, and belongs to the technical field of immunodetection. The monoclonal antibody combination disclosed by the invention comprises a monoclonal antibody 15F4 and a monoclonal antibody 32H9. On the basis of the monoclonal antibody combination, a double-antibody sandwich ELISA detection method with 15F4 as a capture antibody and enzyme-labeled 32H9 as a detection antibody is established, and key parameters such as coating concentration, closing conditions, incubation and color development time and the like are optimized. The method has high specificity on brucella, and does not cross with common cross-reactive bacteria such as escherichia coli O: 157, salmonella and the like; the sensitivity is high, and the detection limit can reach 1 * 10 < 5 > CFU / mL; the repeatability is good, and the intra-batch and inter-batch variation coefficients are both smaller than 10%. The invention provides a core reagent and a reliable means for early, rapid and accurate diagnosis of brucellosis, and is suitable for on-site screening of clinical samples and animal epidemic diseases.

The present invention relates to the field of enzyme-linked immunosorbent assay technology, and more particularly to a hapten, antigen, antibody, and enzyme-linked immunosorbent assay kit for detecting creatine content. The present invention also discloses the use of the hapten in the antigen, antibody, and enzyme-linked immunosorbent assay kit. The enzyme-linked immunosorbent assay kit developed for the hapten used to detect creatine content can achieve rapid detection of large quantities of samples to be tested. It is easy to use, has low detection cost, and is efficient, accurate, and rapid. It can simultaneously detect large quantities of samples and is suitable for detecting creatine content.

The invention relates to the technical field of biomedical detection, in particular to a preparation method and application of a biotinylated antibody without purification. The specific quenching agent is added into a reaction system, residual active ester is sealed in situ, so that the detection antibody which can be directly used for ELISA is directly obtained, traditional ultrafiltration or gel filtration purification is omitted, the preparation period is shortened by at least 2-3 hours, and activity loss of the antibody caused by centrifugation or dilution is avoided; the residual NHS-ester is quenched in situ by a quenching agent, so that a background signal is remarkably reduced, and the signal-to-noise ratio is improved (the signal-to-noise ratio in an I-C system is improved by more than or equal to 50%); the method provided by the invention can also be popularized to an antibody-enzyme coupling system of heterobifunctional cross-linking agents such as EMCS, Sulfo-SMCC and the like, and the ELISA performance is equivalent to that of a traditional purified product; the kit is suitable for clinical scenes such as acute myocardial infarction needing rapid diagnosis, and a high-throughput and low-cost detection platform can be conveniently established.

This invention belongs to the field of reagent detection technology and discloses a diagnostic kit for P200 type pemphigus. The kit comprises human dermal extract protein strips, LM521 / LM421 / LM411 / LM111 recombinant protein strips, a positive control, a negative control, enzyme-labeled IgG antibody, enzyme-labeled IgA antibody, reaction buffer, washing buffer, and enzyme matrix solution. This invention simplifies the complex immunoblotting technique, using human dermal extract and various LMγ1 recombinant protein mixtures as antigens, and simultaneously analyzing IgG and IgA autoantibodies. It comprehensively solves the serological diagnostic problem of P200 type pemphigus in one step.

The application discloses an antibody protective agent for pre-coated antibody enzyme labeled plates, and the protective agent comprises the following components: 1-4% tetrahydropyrimidine and 4-8% mannitol in terms of mass percentage. The antibody protective agent can effectively improve the storage period and stability of the pre-coated enzyme labeled plate after being opened based on the specific combination of tetrahydropyrimidine and mannitol, and can promote the pre-coated enzyme labeled plate using the antibody protective agent to be stably stored for one month at 25 DEG C after being opened, and the real-time stability at 2-8 DEG C can be as long as 12 months.

A compound having the structure (I) is provided. The compound is useful as a therapeutic agent in the form of a lipoplex, or in a form of a polyplex, in a form of a lipid nanoparticle, or in a form of a liposome, or in a form of a micelle, or in a form of an emulsion including a drug, vaccine, oligonucleotide, antibody, enzyme, protein, small molecule, or nucleotide.

A compound having the structure (I) is provided. The compound is useful as a therapeutic agent in the form of a lipoplex, or in a form of a polyplex, in a form of a lipid nanoparticle, or in a form of a liposome, or in a form of a micelle, or in a form of an emulsion including a drug, vaccine, oligonucleotide, antibody, enzyme, protein, small molecule, or nucleotide.

This invention relates to a double-antibody sandwich ELISA kit for detecting serum PTGS1 protein, comprising: a PTGS1 capture antibody, an unlabeled PTGS1 detection antibody, an enzyme-labeled IgG secondary antibody, a solid-phase carrier, an enzyme substrate, a blocking buffer, a washing buffer, and a stop solution; the IgG secondary antibody specifically binds to the PTGS1 detection antibody; the PTGS1 capture antibody is a rabbit monoclonal antibody that specifically binds to the linear epitope A of human PTGS1 protein, the amino acid sequence of which is SEQ ID NO:1, corresponding to amino acids 271-282 of human PTGS1 protein; the PTGS1 detection antibody is a mouse monoclonal antibody that specifically binds to the B epitope of human PTGS1 protein; the amino acid sequences of the B epitope at the A epitope do not overlap and do not constitute steric hindrance. This kit avoids the conserved homologous region between PTGS1 and its homologous protein PTGS2, ensuring the accuracy of the capture antibody recognition, and uses an indirect detection mode with enzyme-labeled goat anti-mouse IgG secondary antibody to achieve signal cascade amplification, significantly improving detection sensitivity.

The invention discloses a molecularly imprinted electrochemical sensing chip for field detection and a trace analysis method, and belongs to the field of electrochemical analysis. According to the method, a working electrode and a counter electrode of the sensing chip are prepared through silk-screen printing conductive carbon ink, and in the preparation process of the working chip, an auxiliary modified mesoporous silica film and an Arg molecular imprinting are connected through a reduced graphene oxide layer; a reference electrode is prepared through silk-screen printing of Ag-AgCl slurry; the molecularly imprinted electrochemical sensor based on the mesoporous silica film is obtained; the problems that a traditional chip depends on specific binding of natural biological elements (such as antibodies and enzymes), is prone to environmental interference, high in cost and poor in stability are solved, and the effects of being low in cost, more suitable for on-site rapid screening of complex samples and suitable for trace detection are achieved.

Methods for target, biomarker, and patient selection discovery in central nervous system disorders utilizing patient-derived cellular models, spatial proteomics, and machine learning. The method generates neural cells from forebrain regions from induced pluripotent stem cells, performs cell-type specific proteome profiling using antibody-enzyme conjugates and spatial proteome profiling, and applies statistical data augmentation to sparse biological datasets. Machine learning classifiers with SHAP-based feature importance identify ranked biomarkers from mass spectrometry data. The platform enables patient stratification by linking molecular signatures to symptom severity, drug screening through biomarker modulation, and diagnostic applications. Kits comprising antibodies for biomarkers including antibodies for biomarkers identified by the method facilitate implementation. Applications include autism spectrum disorder, rare neurodevelopmental disorders, schizophrenia, epilepsy, Alzheimer's disease, and Parkinson's disease.

The present application relates to hybridoma cell strain zqm4B4, and an anti-aspergillus niger monoclonal antibody produced by the hybridoma cell strain and application thereof. The hybridoma cell strain zqm4B4 provided by the present application can be used to prepare an anti-aspergillus niger monoclonal antibody with high titer, and the titer measured by enzyme-linked immunosorbent assay (ELISA) can reach 6.51x10 5 The anti-aspergillus niger monoclonal antibody provided by the present application has high sensitivity and good specificity, and the minimum detection limit for aspergillus niger is 0.0962 μg / mL, and has no cross reaction with other fungi.

The invention provides an anti-neocrown N protein human monoclonal antibody, an enzyme-linked immunosorbent assay kit and application of the anti-neocrown N protein human monoclonal antibody and the enzyme-linked immunosorbent assay kit. The anti-neocoronal N protein human monoclonal antibody is obtained from N protein of human immune neocoronal virus, a heavy chain and a light chain of the anti-neocoronal N protein human monoclonal antibody have variable regions and complementary determining regions, and the anti-neocoronal N protein human monoclonal antibody is specifically combined with neocoronal N protein; and through paired use of the antibodies, the kit has strong anti-interference capability, good specificity and high sensitivity on clinical new crown detection.

The invention relates to a method for detecting the nicotine dissolution rate of a nicotine bag and application. The method comprises the following steps: immersing the nicotine bag in a solvent to obtain a nicotine bag content extracting solution, sampling the nicotine bag content extracting solution at intervals, centrifuging, and taking supernate to obtain a sample to be detected; pre-coating the nicotine antigen to the bottom of the pore plate by using a coating agent; adding the to-be-detected sample into a pore plate, adding at least two nicotine antibody enzyme markers at the same time, incubating, and washing after the incubation is finished; adding at least two color developing agents into the pore plate, uniformly mixing, and incubating and developing in a dark place; after the chromogenic reaction is finished, adding a stop solution into the pore plate, uniformly mixing, and measuring an absorbance value; and calculating the concentration of nicotine in the to-be-detected sample through the standard curve.

The invention relates to a double-antibody sandwich ELISA kit for detecting serum PTGS1 protein. The double-antibody sandwich ELISA kit comprises a PTGS1 capture antibody, a non-labeled PTGS1 detection antibody, an enzyme-labeled IgG secondary antibody, a solid-phase carrier, an enzyme substrate, a confining liquid, a washing liquid and a stop solution, the IgG secondary antibody can be specifically combined with the PTGS1 detection antibody; the PTGS1 capture antibody is a rabbit monoclonal antibody specifically combined with a human PTGS1 protein A linear epitope, the amino acid sequence of the A linear epitope is SEQ ID NO: 1, and the A linear epitope corresponds to the 271th to 282th amino acids of the human PTGS1 protein; the PTGS1 detection antibody is a mouse monoclonal antibody which is specifically combined with a human PTGS1 protein B epitope; and the amino acid sequence of the B epitope at the A epitope is not overlapped and does not form steric hindrance. According to the kit, conserved homologous segments of PTGS1 and homologous protein PTGS2 are avoided, the recognition accuracy of a captured antibody is ensured, signal cascade amplification is realized by adopting an indirect detection mode of an enzyme-labeled goat anti-mouse IgG secondary antibody, and the detection sensitivity is remarkably improved.

The application discloses a method for combined analysis of high-sensitivity cardiac troponin and copeptin for non-diagnostic purposes, and belongs to the technical field of protein detection. The method comprises the following steps: separating a plasma sample through centrifugation, preparing a phosphate buffer for dilution, and preparing a sample for detection; constructing an immune analysis system on a multi-well plate by adopting a double-antibody sandwich method, sequentially performing coating, cleaning, blocking, and preparing a standard sample and a labeled antibody; adding the sample and the standard sample into a detection plate, sequentially performing incubation, adding a detection antibody, and adding enzyme-labeled avidin, and finally developing color and measuring absorbance; collecting detection data to establish a standard curve, calculating a sample concentration by using a double-index collaborative correction model, and performing cross-validation and abnormal value processing. According to the scheme, more stable quantitative results can be obtained, and the anti-interference capability of data detection is enhanced.

The invention discloses an antibody protective agent for a pre-coated antibody elisa plate, and the protective agent comprises the following components in percentage by mass: 1%-4% of ectoine and 4%-8% of mannitol. The antibody protective agent can effectively prolong the storage life and improve the stability of the unsealed pre-coated elisa plate based on the specific combination of ectoine and mannitol, and can promote the unsealed pre-coated elisa plate using the antibody protective agent to be stably stored for one month at 25 DEG C; and the real-time stability at 2-8 DEG C can be efficiently stored for 12 months.

A method for producing a κ light chain antibody having enzyme activity or improved enzyme activity includes modifying a polynucleotide that encodes a κ light chain antibody having a polypeptide having an amino acid sequence where the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is a proline residue, to delete or substitute the proline residue and to obtain a polynucleotide that encodes a κ light chain antibody having a polypeptide having an amino acid sequence where the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is deleted or substituted with an amino acid residue other than a proline residue, and expressing a κ light chain antibody having enzyme activity in an intracellular or extracellular expression system by using an expression vector including the polynucleotide that encodes a κ light chain antibody obtained after modification.

The present invention relates to a hybridoma cell line VAND8 and an anti-vanillin monoclonal antibody produced therefrom and its application, belonging to the field of immunochemistry. The hybridoma cell line VAND8 provided by the present invention can be used to prepare a high-titer anti-vanillin monoclonal antibody, with a titer of up to 3.2×10 5 The anti-vanillin monoclonal antibody provided by the present invention has high sensitivity and good specificity, and its 50% inhibitory concentration IC 50 The content of vanillin was 22.1 μg / mL, and the cross-reaction rate with vanillin structural analogues was low or even no cross-reaction; it can be used to determine the content of vanillin.

The application relates to a KIM-1 chemiluminescence kit. The application discloses a KIM-1 chemiluminescence kit, which comprises sample buffer, magnetic bead labeled antibody magnetic bead working solution, alkaline phosphatase coupled kidney injury factor 1 monoclonal antibody enzyme working solution, calibrant and quality control product. The sample buffer comprises reagent 1 and reagent 2. The reagent 1 comprises 2-5% polyethylene glycol-2000, 0.1-0.5% ethylenediaminetetraacetic acid, 5-7% antioxidant IR1010, 50-60% PB buffer, 20-30% toluene and 10-15% formaldehyde. The reagent 2 comprises 5-10% bovine serum albumin, 25-30% NaCl, 3-5% mannitol, 5-10% glycine, 1-5% ethylenediaminetetraacetic acid disodium, 5-9% PVP-10, 30-40% dehydrogenated serum, 0.1-0.5% non-ionic surfactant, 1-5% preservative and 0.1-1.5% LowCross-Buffer. The sample buffer in the KIM-1 chemiluminescence kit prepared by using the application can be used for diluting and storing the sample (urine / serum) after being separated from the body within 0-2h, so that the long-term stability of the sample can be ensured, and the sample is suitable for large-batch detection.